British Trade Commissioner: Saudi Arabia is the Largest Destination of UK Exports in the Region

Simon Penney, the British Trade Commissioner (HTMC) for the Middle East and Pakistan.
Simon Penney, the British Trade Commissioner (HTMC) for the Middle East and Pakistan.
TT

British Trade Commissioner: Saudi Arabia is the Largest Destination of UK Exports in the Region

Simon Penney, the British Trade Commissioner (HTMC) for the Middle East and Pakistan.
Simon Penney, the British Trade Commissioner (HTMC) for the Middle East and Pakistan.

Simon Penney, the British Trade Commissioner (HTMC) for the Middle East and Pakistan, said Saudi-British efforts were underway to increase and maximize partnerships and corporate business in various fields.

He noted that Riyadh represented the largest destination for UK exports, with an increase of 24 percent over the last three years, stressing that the two kingdoms enjoyed a strong long-term bilateral relationship, based on a number of pillars, including trade and investment.

In an interview with Asharq Al-Awsat, Penney said opportunities abound in all the diverse sectors of the economy in Saudi Arabia.

He added that his team at the Department for International Trade was working closely with the Invest in Saudi Arabia initiative and the Ministry of Investment on many of the huge Saudi projects, with the aim to encourage British companies to invest in Saudi Arabia.

“Of course, investment goes both ways, and we are looking to thrive and increase business in the UK and Saudi Arabia,” Penney stated.

According to the British official, the partnership between the two kingdoms continues to grow on solid bases. Referring to trade statistics for the end of the first quarter of 2022, Penney said that Saudi Arabia was the largest destination for UK exports in the region, due to the significant growth in service exports from the UK, which has increased by 24 percent over the past three years.

Total trade in goods and services (export and import) between the UK and Saudi Arabia amounted to £11.3 billion in the four quarters to the end of the first quarter of 2022, an increase of 6.4 percent, or £683 million, he told Asharq Al-Awsat.

On the United Kingdom’s readiness to cooperate with Saudi Arabia in the medical and health care sector, Penney stressed that health care and life sciences were essential for both kingdoms, noting that cooperation in this field was an important part of the British bid for the Kingdom’s Vision 2030.

Penney, who recently participated in the Global Health Forum in Riyadh, stressed his country’s readiness to provide, through British health care experts, advice and participation in many health care initiatives in Saudi Arabia, noting that after the Covid-19 pandemic, the opportunities for cooperation in these sectors increased significantly.

He said that the forum provided a great opportunity to invest in diagnostic technology and remote care, adding that the participating British delegation represented the best innovators in the field of digitization and healthcare transformation, and reflected the UK’s commitment to strengthening healthcare partnerships with Riyadh.

“We participated in the Global Health Exhibition in Riyadh with a high-level delegation from 26 British organizations, and we traveled to Riyadh, Jeddah and Dammam. The delegation included five institutions affiliated with the National Health Service, which together provide a range of important and specialized services, including primary care, mental health services, education and training, out-of-hospital services, and digital services,” Penney told Asharq Al-Awsat.

The British delegation to the forum was one of the largest trade missions from the United Kingdom in the field of health care and life sciences to Saudi Arabia, he revealed. It included the NHS Trust, in addition to MedTech, Genomics, Digital Health and Health Care Services, in partnership with Mott MacDonald and Health Care World.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.